Key Takeaways Ashland introduces pricing actions across portfolios to manage volatility in energy, materials and logistics.ASH adjusts pricing by product and region to offset procurement, supply chain, and operating cost pressures.The pricing adjustments are needed to sustain a reliable supply to customers.Ashland Inc. (ASH) has announced an implantation of a series of pricing actions across Life Sciences, Intermediates, Personal Care and Specialty Additives product portfolios. This is in response to the on ...

Wilmington, Del., March 23, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) is implementing pricing actions across its Life Sciences, Intermediates, Personal Care and Specialty Additives product portfolios globally in response to continued volatility in energy markets, raw material costs and logistics conditions stemming from the conflict in the Middle East. The company is taking proactive actions across procurement, supply chain and operations to actively manage costs where possible, while adjusting pric ...

PresentationSo it is now my pleasure to introduce Ashland Global Holdings. We are delighted to have William Whitaker, who was promoted Chief Financial Officer in July of 2025. Congratulations.Rosemarie MorbelliGabelli & Company Investment Advisers, Inc. So while in his new role, since he joined Ashland in 2015, William has held positions of increasing responsibilities in Corporate Development, Treasury and Financial Planning, among others. And importantly, he had the pleasure of talking to all of us as Inve ...

Group 1 - The symposium will feature discussions on industry dynamics, current trends, business fundamentals, and specialty chemicals investing [2] - William C. Whitaker, CFO of Ashland, will participate in a fireside chat and host one-on-one meetings with institutional investors [1] - Ashland is a global additives and specialty ingredients company focused on environmental, social, and governance (ESG) initiatives [2] Group 2 - Ashland serves a diverse range of markets including architectural coatings, construction, energy, food and beverage, personal care, and pharmaceuticals [2] - The company operates in over 100 countries with approximately 2,900 employees dedicated to solving complex problems for customers [2]

Group 1: Townsquare Media - Townsquare Media (NYSE: TSQ) is transitioning to a digital business model, with digital revenue now accounting for 55% of total net revenue [1] - Q3 2025 revenue decreased by 7.4% year-over-year to $106.76 million, but excluding political advertising, the decline was only 4.5% [1] - The company reported an EPS of $0.05, beating the estimate of $0.03, and the stock has increased by 43.45% year-to-date [1] - Management has been actively buying shares, with CEO Bill Wilson purchasing over 700,000 units at $5.41 per share [1] - The stock trades at $7.17, with a trailing P/E of 6x and a dividend yield of approximately 10.8% [1] Group 2: Vestis - Vestis (NYSE: VSTS) specializes in renting uniforms and workplace supplies, having spun out of Aramark in late 2023 [1] - Free cash flow surged to $28.3 million in Q1 FY2026, a significant increase from nearly zero in the prior year [1] - Operating cash flow reached $37.69 million, and adjusted EBITDA grew from $64.66 million in Q4 2025 to $70.38 million in Q1 FY2026 [1] - The company aims for at least $75 million in annual cost savings by the end of FY2026 [1] - Despite improvements, revenue fell 3% year-over-year to $663.39 million, and net leverage remains high at 4.83x [1] Group 3: Ashland - Ashland (NYSE: ASH) produces specialty chemicals for pharmaceuticals, personal care, and industrial applications [1] - Life Sciences revenue increased by 4% year-over-year to $139 million, with segment adjusted EBITDA rising 11% to $31 million [1] - Free cash flow was reported at $111 million, aided by a $103 million tax refund from a divestiture [1] - The company narrowed its FY2026 adjusted EBITDA guidance to $400 million to $420 million, targeting double-digit adjusted EPS growth [1] - The stock is currently trading at $50.98, down 12.53% year-to-date, with an analyst consensus price target of $68 [1]

Core Viewpoint - Ashland's recent earnings report indicates a mixed performance, with a loss from continuing operations but an adjusted earnings beat, raising questions about future performance trends leading up to the next earnings release [1][2]. Financial Performance - For Q1 fiscal 2026, Ashland reported a loss of $14 million or 30 cents per share, an improvement from a loss of $166 million or $3.51 per share in the same quarter last year [2]. - Adjusted earnings were 26 cents per share, slightly down from 28 cents year-over-year, but above the Zacks Consensus Estimate of 23 cents [2]. - Total sales decreased by 5% year-over-year to $386 million, missing the Zacks Consensus Estimate of $408.3 million [3]. Segment Highlights - **Life Sciences**: Sales increased by 4% year-over-year to $139 million, though it fell short of the Zacks Consensus Estimate of $146 million, driven by resilient demand in pharma applications [4]. - **Personal Care**: Sales declined by 8% year-over-year to $123 million, missing the Zacks Consensus Estimate of $132 million, primarily due to portfolio optimization linked to the Avoca divestiture [5]. - **Specialty Additives**: Sales fell by 11% year-over-year to $102 million, missing the Zacks Consensus Estimate of $111 million, attributed to weak demand in coatings, particularly in China [6]. - **Intermediates**: Sales decreased by 6% year-over-year to $31 million, slightly beating the consensus estimate of $30.26 million, mainly due to lower pricing amid an oversupplied market [7]. Financial Position - Cash and cash equivalents stood at $304 million at the end of the quarter, reflecting a sequential increase of approximately 41.4% [8]. - Long-term debt was reported at $1,387 million, showing a slight increase of about 0.2% from the previous quarter [8]. Outlook - For fiscal 2026, Ashland anticipates sales between $1.835 billion and $1.905 billion, with adjusted EBITDA projected at $400 million to $420 million [9]. - Adjusted EPS is expected to show double-digit growth due to operational improvements and portfolio optimization, with free cash flow conversion targeted at around 50% of adjusted EBITDA [9]. Estimate Trends - There has been a downward trend in estimates, with the consensus estimate shifting down by 7.92% over the past month [10][11]. - Ashland currently holds a Zacks Rank of 3 (Hold), indicating expectations for an in-line return in the coming months [13]. VGM Scores - Ashland has an average Growth Score of C, a Momentum Score of B, and a Value Score of B, placing it in the top 40% for the value investment strategy [12].

Company Overview - Ashland Inc. (ASH) is a specialty chemicals company that has shifted its focus from commodity chemicals to specialized products, aiming to serve a diverse range of industries [1]. Investment Insights - The Stock Orchard, a former buy-side equity analyst and portfolio manager, emphasizes a long-only investment strategy without style bias, focusing on areas such as 'value with a catalyst', steady compounders, and potential multi-baggers [1].

Core Insights - Gabelli Funds will host its 17th Annual Specialty Chemicals Symposium on March 19, 2026, in Midtown Manhattan, focusing on industry dynamics, current trends, and business fundamentals in the specialty chemicals sector [1][2]. Group 1: Event Details - The symposium will feature discussions with leading companies and organizations within the specialty chemicals ecosystem [1]. - Attendees will have the opportunity for one-on-one meetings with management teams, and a webcast option will be available for those unable to attend in person [2]. Group 2: Presenting Companies - The symposium will include presentations from notable companies such as Arq, Inc., Ashland Global, BASF SE, and The Chemours Company, among others [3]. - A total of 12 companies are listed as presenters, with some indicating virtual attendance options [3][4].

Group 1 - Ashland Inc. is recognized as one of the 9 undervalued chemical stocks to buy according to hedge funds [1] - Morgan Stanley raised its price target for Ashland Inc. from $60 to $63 while maintaining an Equal Weight rating, citing stronger peer valuations despite a minor decrease in FY26 EBITDA predictions [2] - The U.S. Environmental Protection Agency (EPA) accepted Ashland's application for its agrimer eco-coat polymer seed coating, allowing it to be used in food and non-food pesticide formulations [3][4] Group 2 - The approval of the eco-coat polymer enhances Ashland's prospects for global commercialization of sustainable crop-care products and potential collaborations with clients and partners [4] - Ashland Inc. operates as a global specialty chemicals company, focusing on innovation and sustainability across various industries, including pharmaceuticals, coatings, adhesives, and personal care [5]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]